The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Valproate, an anticonvulsant drug used to treat bipolar disorder, was studied for its ability to promote neurogenesis from embryonic rat cortical or striatal primordial stem cells. Six days of valproate exposure increased by up to fivefold the number and percentage of tubulin β III‐immunopositive neurons, increased neurite outgrowth, and decreased by fivefold the number of astrocytes without changing the number of cells. Valproate also promoted neuronal differentiation in human fetal forebrain stem cell cultures. The neurogenic effects of valproate on rat stem cells exceeded those obtained with the neurotrophins brain‐derived growth factor (BDNF) or NT‐3, and slightly exceeded the effects obtained with another mood stabilizer, lithium. No effect was observed with carbamazepine. Most of the newly formed neurons were GABAergic, as shown by 10‐fold increases in neurons that immunostained for GABA and the GABA‐synthesizing enzyme GAD65/67. Double immunostaining for bromodeoxyuridine and tubulin β III showed that valproate increased by four‐ to fivefold the proliferation of neuronal progenitors derived from rat stem cells and increased cyclin D2 expression. Valproate also regulated the expression of survival genes, Bad and Bcl‐2, at different times of treatment. The expression of prostaglandin E synthase, analyzed by quantitative RT‐PCR, was increased by ninefold as early as 6 h into treatment by valproate. The enhancement of GABAergic neuron numbers, neurite outgrowth, and phenotypic expression via increases in the neuronal differentiation of neural stem cell may contribute to the therapeutic effects of valproate in the treatment of bipolar disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subgenual prefrontal cortex abnormalities in mood disorders
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, M. E. (1997) · Nature · doi:10.1038/386824a0 · Cited by 2,693 · cited 1×
“…studies have identified regional atrophic changes in the brains of bipolar disorder patients, including ventricular enlargements and reductions of gray matter volume (Drevets et al. 1997; Soares and Mann 1997; Hauser et al. 2000; Moore et al. 2000; Lopez-Larson et al. 2002; Strakowski et al. 2002).”
BackgroundPhiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 1×
“Trichostatin A, a potent HDAC inhibitor, caused hyperacetylation of histone H3 and H4 in cortical stem cells, whereas the valproate analog valpromide, devoid of HDAC inhibition (Gottlicher et al. 2001; Phiel et al. 2001), had no effect (Fig.”
BackgroundGABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082 · cited 2×
“…neurons in the CA2 region contain less mRNA for the two c-aminobutyric acid (GABA)-synthesizing enzymes, GAD 65 and 67 (Benes et al. 1998; Benes and Berretta 2001; Knable et al. 2001; Heckers et al. 2002), and less reelin, a protein that is expressed specifically in GABAergic…”
BackgroundA reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives
Benes, F. M., Kwok, E. W., Vincent, S. L., & Todtenkopf, M. S. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00138-3 · Cited by 470
Beasley, C. L., Zhang, Z. J., Patten, I., & Reynolds, G. P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01360-4 · Cited by 374 · cited 1×
“The prefrontal cortex of bipolar disease patients contains fewer nonpyramidal neurons, particularly those of a GABAergic phenotype (Knable 1999; Beasley et al. 2002).”
BackgroundHeckers, S., Stone, D., Walsh, J., Shick, J., Koul, P., & Benes, F. M. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.521 · Cited by 322
Molecular mechanisms of sleep‐wake regulation: roles of prostaglandins D 2 and E 2
Hayaishi, O. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907936 · Cited by 235
Hauser, P., Matochik, J., Altshuler, L. L., Denicoff, K. D., Conrad, A., Li, X., & Post, R. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00154-8 · Cited by 143
Cited by
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences
Romoli, M., Mazzocchetti, P., D'Alonzo, R., Siliquini, S., Rinaldi, V. E., Verrotti, A., Calabresi, P., & Costa, C. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666181227165722 · Cited by 372
Huang, H.-S., Matevossian, A., Whittle, C., Kim, S. Y., Schumacher, A., Baker, S. P., & Akbarian, S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3272-07.2007 · Cited by 352
Zhou, R., Yuan, P., Wang, Y., Hunsberger, J. G., Elkahloun, A., Wei, Y., Damschroder-Williams, P., Du, J., Chen, G., & Manji, H. K. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.131 · Cited by 316
Wu, X., Chen, P. S., Dallas, S., Wilson, B., Block, M. L., Wang, C.-C., Kinyamu, H., Lu, N., Gao, X., Leng, Y., et al. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009024 · Cited by 315
Metadata
- Authors
- Laeng, P., Pitts, R. L., Lemire, A. L., Drabik, C. E., Weiner, A., Tang, H., Thyagarajan, R., Mallon, B. S., & Altar, C. A.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2004-09-06
- Volume
- 91
- Issue
- 1
- Pages
- 238-251
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1994514343
- Cited by
- 169
- References
- 8
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.